参考文献/References:
[1].Guo L,Fu B,et al. Diuretic resistance in patients with kidney disease:challenges and opportunities[J]. Biomed Pharmacother,2023,157:114058.
[2].Wilcox CS,Testani JM,Pitt B. Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure[J]. Hypertension,2020,76(4):1045-1054.
[3].[3] Rahman R,Paz P,Elmassry M,et al. Diuretic resistance in heart failure[J]. Cardiol Rev,2021,29(2):73-81.
[4].[4] Felker GM,Ellison DH,et al. Diuretic therapy for patients with heart failure:JACC state-of-the-art review[J]. J Am Coll Cardiol,2020,75(10):1178-1195.
[5].[5] Kim JA,Wu L,Rodriguez M,et al. Recent developments in the evaluation and management of cardiorenal syndrome:a comprehensive review[J]. Curr Probl Cardiol,2023,48(3):101509.
[6].[6] Guazzi M,Gatto P,Giusti G,et al. Pathophysiology of cardiorenal syndrome in decompensated heart failure:role of lung-right heart-kidney interaction[J]. Int J Cardiol,2013,169(6):379-384.
[7].[7] Cox ZL,Rao VS,Testani JM. Classic and novel mechanisms of diuretic resistance in cardiorenal syndrome[J]. Kidney360,2022,3(5):954-967.
[8].[8] Rao VS,Planavsky N,Hanberg JS,et al. Compensatory distal reabsorption drives diuretic resistance in human heart failure[J]. J Am Soc Nephrol,2017,28(11):3414-3424.
[9].[9] Aronson D. The complexity of diuretic resistance[J]. Eur J Heart Fail,2017,19(8):1023-1026.
[10].[10] Cuthbert JJ,Bhandari S,Clark AL. Hypochloraemia in patients with heart failure:causes and consequences[J]. Cardiol Ther,2020,9(2):333-347.
[11].[11] Masella C,Viggiano D,Molfino I,et al. Diuretic resistance in cardio-nephrology:role of pharmacokinetics,hypochloremia,and kidney remodeling[J]. Kidney Blood Press Res,2019,44(5):915-927.
[12].Shah N,Madanieh R,Alkan M,et al. A perspective on diuretic resistance in chronic congestive heart failure[J]. Ther Adv Cardiovasc Dis,2017,11(10):271-278.
[13].Jardim SI,Ramos Dos Santos L,Araújo I,et al. A 2018 overview of diuretic resistance in heart failure[J]. Rev Port Cardiol(Engl Ed),2018,37(11):935-945.
[14].[14] Adams KF Jr, Fonanow GC,Emerman CL,et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States:rationale,design,and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry(ADHERE)[J]. Am Heart J,2005,1492:209-216.
[15].[15] Heywood JT,Fonarow GC,Costanzo MR,et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure:a report from the ADHERE database[J]. J Card Fail,2007,13(6):422-430.
[16].[16] Ellison DH,Felker GM. Diuretic treatment in heart failure[J]. N Engl J Med,2017,377(20):1964-1975.
[17].[17] Cox ZL,Siddiqi HK,Stevenson LW,et al. Randomized controlled trial of urine chemistry guided acute heart failure treatment (ESCALATE):rationale and design[J]. Am Heart J,2023,265:121-131.
[18]. [18] Jentzer JC,DeWald TA,Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure[J]. J Am Coll Cardiol,2010,56:1527-1534.
[19].[19] Trullàs JC,Morales-Rull JL,Casado J,et al. Combining loop with thiazide diuretics for decompensated heart failure:the CLOROTIC trial[J]. Eur Heart J,2023,44(5):411-421.
[20].[20] Verbrugge FH,Martens P,Ameloot K,et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance[J]. Eur J Heart Fail,2019,21(11):1415-1422.
[21].[21] Mullens W,Dauw J,Martens P,et al. Acetazolamide in acute decompensated heart failure with volume overload[J]. N Engl J Med,2022,387(13):1185-1195.
[22].[22] Malik BA,Nnodebe I,Fayaz A,et al. Effect of acetazolamide as add-on diuretic therapy in patients with heart failure:a meta-analysis[J]. Cureus,2023,15(4):e37792.
[23].[23] Inomata T,Ikeda Y,Kida K,et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment—Results from the K-STAR Study[J]. Circ J,2017,82(1):159-167.
[24].[24] Wang C,Xiong B,Cai L,et al. Effects of tolvaptan in patients with acute heart failure:a systematic review and meta-analysis[J]. BMC Cardiovasc Disord,2017,17(1):164.
[25].Herrington WG,Savarese G,Haynes R,et al. Cardiac,renal,and metabolic effects of sodium-glucose co-transporter 2 inhibitors:a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors[J]. Eur J Heart Fail,2021,23(8):1260-1275.
[26].Wilcox CS,Shen W,Boulton DW,et al. Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects[J]. J Am Heart Assoc,2018,7(4):e007046.
[27].Bowman BN,Nawarskas JJ, Anderson JR. Treating diuretic resistance:an overview[J]. Cardiol Rev,2016,24(5):256-260.
[28].[28]Lai M,Lam JC,Radosevich JJ,et al. Levels of albumin and impact on loop diuretic and albumin co-administration in heart failure[J]. J Cardiovasc Pharmacol,2024,83(3):271-275.
[29].[29]Fernandes J,Costa R,Guerreiro R,et al. Co-administration of albumin and furosemide in acute heart failure with diuretics resistance[J]. Acta Med Port,2023,36(3):193-201.
[30].[30] Griffin M,Soufer A,Goljo E,et al. Real world use of hypertonic saline in refractory acute decompensated heart failure:A U.S. center’s experience[J]. JACC Heart Fail,2020,8(3):199-208.
[31].[31] Diaz-Arocutipa C,Denegri-Galvan J,Vicent L,et al.The added value of hypertonic saline solution to furosemide monotherapy in patients with acute decompensated heart failure:a meta-analysis and trial sequential analysis[J]. Clin Cardiol ,2023,46(8):853-865.
[32].[32] Teo LY,Lim CP,Neo CL,et al. Ultrafiltration in patients with decompensated heart failure and diuretic resistance:an Asian centre’s experience[J]. Singapore Med J,2016,57(7):378-383
[33].[33] López-Vilella R,Guerrero Cervera B,Sánchez-Lázaro I,et al. Therapeutic approach in heart failure with poor diuretic response:peripheral ultrafiltration vs. conventional treatment[J]. ESC Heart Fail,2023,10(4):2290-2297.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(8):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(8):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(8):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(8):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(8):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(8):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]袁静,郭艺芳.利尿剂在降压治疗中的应用[J].心血管病学进展,2015,(6):668.[doi:10.3969/j.issn.1004-3934.2015.06.004]
YUAN Jing,GUO Yifang.Application of Diuretics in Antihypertensive Treatment[J].Advances in Cardiovascular Diseases,2015,(8):668.[doi:10.3969/j.issn.1004-3934.2015.06.004]
[8]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[9]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(8):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[10]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]